SpringWorks Therapeutics (NASDAQ:SWTX) Receives Consensus Recommendation of "Hold" from Brokerages

SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) has been given a consensus recommendation of "Hold" by the eight research firms that are presently covering the firm, Marketbeat.com reports. Seven analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $52.57.

A number of equities analysts have recently issued reports on the company. Barclays restated an "equal weight" rating and issued a $47.00 price target (down from $63.00) on shares of SpringWorks Therapeutics in a research note on Monday, April 28th. Wedbush reissued a "neutral" rating and issued a $47.00 target price (down from $81.00) on shares of SpringWorks Therapeutics in a research report on Monday, April 28th. Evercore ISI lowered shares of SpringWorks Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Monday, April 28th. HC Wainwright reissued a "neutral" rating and issued a $47.00 price objective (down previously from $74.00) on shares of SpringWorks Therapeutics in a report on Wednesday, April 30th. Finally, Guggenheim restated a "neutral" rating and set a $47.00 target price on shares of SpringWorks Therapeutics in a research report on Monday, May 12th.

SpringWorks Therapeutics Stock Performance

Shares of SWTX traded up $0.19 on Tuesday, hitting $46.97. 9,133,757 shares of the stock traded hands, compared to its average volume of 4,176,765. The company has a market capitalization of $3.54 billion, a PE ratio of -13.77 and a beta of 0.70. The business has a 50 day simple moving average of $44.92 and a 200 day simple moving average of $43.94. SpringWorks Therapeutics has a one year low of $28.21 and a one year high of $62.00.

SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) last announced its quarterly earnings results on Friday, May 9th. The company reported ($1.11) EPS for the quarter, missing analysts' consensus estimates of ($0.81) by ($0.30). The company had revenue of $49.09 million during the quarter, compared to the consensus estimate of $64.19 million. SpringWorks Therapeutics had a negative return on equity of 51.10% and a negative net margin of 115.60%. On average, equities analysts expect that SpringWorks Therapeutics will post -2.05 earnings per share for the current year.

Hedge Funds Weigh In On SpringWorks Therapeutics

Several large investors have recently added to or reduced their stakes in SWTX. Boxer Capital Management LLC bought a new stake in shares of SpringWorks Therapeutics during the 4th quarter valued at $123,620,000. Capital International Investors increased its stake in SpringWorks Therapeutics by 92.7% in the 4th quarter. Capital International Investors now owns 2,361,746 shares of the company's stock worth $85,330,000 after buying an additional 1,136,079 shares in the last quarter. Woodline Partners LP increased its stake in SpringWorks Therapeutics by 43.9% in the 1st quarter. Woodline Partners LP now owns 2,144,814 shares of the company's stock worth $94,651,000 after buying an additional 654,678 shares in the last quarter. Pentwater Capital Management LP bought a new stake in SpringWorks Therapeutics during the first quarter valued at about $22,065,000. Finally, Millennium Management LLC lifted its position in shares of SpringWorks Therapeutics by 1,907.4% in the first quarter. Millennium Management LLC now owns 503,868 shares of the company's stock valued at $22,236,000 after acquiring an additional 478,768 shares in the last quarter.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.